Compare stocks

Swedish Orphan Biovitrum AB is a biotechnology company primarily focused on developing and commercializing specialty pharmaceuticals for rare diseases. The company is active in therapeutics for hematology, immunology, and genetic and metabolic disorders. Swedish Orphan Biovitrum was founded in 2001 and is headquartered in Stockholm, Sweden. The company operates globally, reaching markets in Europe, North America, and other regions. A key aspect of its strategic positioning is its commitment to addressing unmet medical needs in rare diseases, which often provides a unique market niche. The company invests significantly in research and development to fuel growth and innovation in its therapeutic areas.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.